Some investors have started pouring funds into biotechnology, finds Financial Times.
FT adds more than $700 million has been invested in companies looking for treatments for diseases like multiple sclerosis and hepatitis C of late despite the potential risks. Read more.
Also check out:
Healthcare was always a topic of dinner-table conversation for John Bell-Irving. With a doctor for a father and head nurse for a mother, he couldn’t escape it.
Biotechnology is one of the most interesting sectors of the stock market. After all, how many other industry groups are full of companies striving to save lives?
Despite powerful science and great talent, financing for Canadian biotechs was flat in 2012.
The healthcare and housing sectors are performing particularly well in America.
Micro-niche ETFs are based on specific sectors, so clients have to research them before investing.